21st Oct 2024 18:21
Sareum Holdings PLC - Cambridge, England-based pharmaceutical company focused on developing next-generation kinase inhibitors for autoimmune disease and cancer - Says it has raised a further GBP1.0 million via a subscription for 4.4 million new shares at 22.5 pence each. Investors included the unnamed institution that took part in its October 11 fundraise. Each subscriber will be issued one five-year warrant, exercisable at the subscription price of 22.5p, representing a 17% discount to the closing market price on October 18. Read More
